Iron-Refractory Iron Deficiency Anemia: Pathophysiological Mechanisms, Hepcidin Dysregulation, and Emerging Diagnostic and Therapeutic Strategies
Iron-refractory iron deficiency anemia (IRIDA) is an uncommon hereditary hematological disorder characterized by persistent microcytic and hypochromic anemia, markedly reduced transferrin saturation, and inadequate hematological response to conventional oral iron supplementation. Its molecular pathogenesis is primarily associated with pathogenic variants in the TMPRSS6 gene, which impair matriptase-2 activity and disrupt physiological suppression of hepcidin, resulting in restricted intestinal iron absorption and reduced systemic iron availability. This narrative review examines the molecular mechanisms, hematological manifestations, diagnostic approaches, and therapeutic strategies associated with hereditary IRIDA, integrating published experimental and clinical evidence within an international framework that considers healthcare accessibility in Latin America. The reviewed findings demonstrate substantial biochemical differences between hereditary IRIDA and acquired iron deficiency anemia, particularly in the transferrin saturation-to-hepcidin ratio, while highlighting the potential diagnostic value of hepcidin-based indices. Hematological investigations reveal considerable phenotypic heterogeneity, including variations in hemoglobin concentration, erythrocyte indices, and iron parameters among individuals with TMPRSS6-associated abnormalities. Therapeutic evidence indicates that intravenous iron may produce partial hematological improvement despite persistent abnormalities in iron regulation, whereas selected patients with IRIDA-related phenotypes may demonstrate variable responses to oral supplementation. Emerging interventions targeting hepcidin synthesis and the hepcidin–ferroportin axis offer promising mechanistic approaches, although their clinical effectiveness requires further validation. The available evidence remains limited by small patient populations, heterogeneous diagnostic criteria, and insufficient comparative therapeutic investigations. Overall, the findings emphasize distinguishing hereditary IRIDA from acquired refractory iron deficiency through integrated clinical, biochemical, and molecular assessment.
Authors
- Luis Miguel Mora López (ORCID: https://orcid.org/0009-0005-8061-1569)
Publication Details
- Journal
- IECCMEXICO
- Published
- 2026-11-15
- DOI
- https://doi.org/10.64784/405
- Primary Topic
- Iron Metabolism and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00